Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib

Yuxia Jia, Siraj M. Ali, Shumaila Saad, Courtney A. Chan, Vincent A. Miller, Balazs Halmos

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We report the case of a young, never-smoker woman with Li-Fraumeni syndrome and advanced lung adenocarcinoma refractory to multiple lines of conventional chemotherapy and negative for actionable alterations by routine testing. Comprehensive genomic profiling by clinical-grade next generation sequencing was performed on 3320 exons of 184 cancer-related genes and 37 introns of 14 genes frequently rearranged in cancer. The tumor was found to harbor both EGFR L858R and ERBB2 S310F alterations and also tested positive for a known TP53 germline mutation. The presence of the EGFR mutation was further validated by direct sequencing. Based on these results, a dual EGFR/ERBB2 inhibitor, afatinib, was chosen for treatment. The patient achieved a rapid, complete, and durable response to afatinib monotherapy, both clinically and radiographically. The treatment was very well tolerated. This unique case raises practical questions as to the challenges of molecular testing and highlights the potential association of p53 mutations with concurrent EGFR and ERBB2 aberrations. As this case powerfully illustrates, the combination of broad genomic profiling and targeted therapy guided by mutational analysis offers the possibility of precision management of refractory advanced adenocarcinoma in the background of neoplastic syndromes.

Original languageEnglish (US)
Pages (from-to)970-974
Number of pages5
JournalCancer Biology and Therapy
Volume15
Issue number8
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Li-Fraumeni Syndrome
Mutation
Germ-Line Mutation
Neoplasm Genes
Introns
Exons
Neoplasms
Adenocarcinoma
Therapeutics
Drug Therapy
Genes
Adenocarcinoma of lung
BIBW 2992

Keywords

  • Afatinib
  • EGFR
  • ERBB2
  • Genomic profiling
  • Li-Fraumeni syndrome
  • Lung cancer
  • Next generation sequencing

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology
  • Medicine(all)

Cite this

Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib. / Jia, Yuxia; Ali, Siraj M.; Saad, Shumaila; Chan, Courtney A.; Miller, Vincent A.; Halmos, Balazs.

In: Cancer Biology and Therapy, Vol. 15, No. 8, 2014, p. 970-974.

Research output: Contribution to journalArticle

@article{5b299a8102fd4d27af33e1ee9ff87055,
title = "Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib",
abstract = "We report the case of a young, never-smoker woman with Li-Fraumeni syndrome and advanced lung adenocarcinoma refractory to multiple lines of conventional chemotherapy and negative for actionable alterations by routine testing. Comprehensive genomic profiling by clinical-grade next generation sequencing was performed on 3320 exons of 184 cancer-related genes and 37 introns of 14 genes frequently rearranged in cancer. The tumor was found to harbor both EGFR L858R and ERBB2 S310F alterations and also tested positive for a known TP53 germline mutation. The presence of the EGFR mutation was further validated by direct sequencing. Based on these results, a dual EGFR/ERBB2 inhibitor, afatinib, was chosen for treatment. The patient achieved a rapid, complete, and durable response to afatinib monotherapy, both clinically and radiographically. The treatment was very well tolerated. This unique case raises practical questions as to the challenges of molecular testing and highlights the potential association of p53 mutations with concurrent EGFR and ERBB2 aberrations. As this case powerfully illustrates, the combination of broad genomic profiling and targeted therapy guided by mutational analysis offers the possibility of precision management of refractory advanced adenocarcinoma in the background of neoplastic syndromes.",
keywords = "Afatinib, EGFR, ERBB2, Genomic profiling, Li-Fraumeni syndrome, Lung cancer, Next generation sequencing",
author = "Yuxia Jia and Ali, {Siraj M.} and Shumaila Saad and Chan, {Courtney A.} and Miller, {Vincent A.} and Balazs Halmos",
year = "2014",
doi = "10.4161/cbt.29173",
language = "English (US)",
volume = "15",
pages = "970--974",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "8",

}

TY - JOUR

T1 - Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib

AU - Jia, Yuxia

AU - Ali, Siraj M.

AU - Saad, Shumaila

AU - Chan, Courtney A.

AU - Miller, Vincent A.

AU - Halmos, Balazs

PY - 2014

Y1 - 2014

N2 - We report the case of a young, never-smoker woman with Li-Fraumeni syndrome and advanced lung adenocarcinoma refractory to multiple lines of conventional chemotherapy and negative for actionable alterations by routine testing. Comprehensive genomic profiling by clinical-grade next generation sequencing was performed on 3320 exons of 184 cancer-related genes and 37 introns of 14 genes frequently rearranged in cancer. The tumor was found to harbor both EGFR L858R and ERBB2 S310F alterations and also tested positive for a known TP53 germline mutation. The presence of the EGFR mutation was further validated by direct sequencing. Based on these results, a dual EGFR/ERBB2 inhibitor, afatinib, was chosen for treatment. The patient achieved a rapid, complete, and durable response to afatinib monotherapy, both clinically and radiographically. The treatment was very well tolerated. This unique case raises practical questions as to the challenges of molecular testing and highlights the potential association of p53 mutations with concurrent EGFR and ERBB2 aberrations. As this case powerfully illustrates, the combination of broad genomic profiling and targeted therapy guided by mutational analysis offers the possibility of precision management of refractory advanced adenocarcinoma in the background of neoplastic syndromes.

AB - We report the case of a young, never-smoker woman with Li-Fraumeni syndrome and advanced lung adenocarcinoma refractory to multiple lines of conventional chemotherapy and negative for actionable alterations by routine testing. Comprehensive genomic profiling by clinical-grade next generation sequencing was performed on 3320 exons of 184 cancer-related genes and 37 introns of 14 genes frequently rearranged in cancer. The tumor was found to harbor both EGFR L858R and ERBB2 S310F alterations and also tested positive for a known TP53 germline mutation. The presence of the EGFR mutation was further validated by direct sequencing. Based on these results, a dual EGFR/ERBB2 inhibitor, afatinib, was chosen for treatment. The patient achieved a rapid, complete, and durable response to afatinib monotherapy, both clinically and radiographically. The treatment was very well tolerated. This unique case raises practical questions as to the challenges of molecular testing and highlights the potential association of p53 mutations with concurrent EGFR and ERBB2 aberrations. As this case powerfully illustrates, the combination of broad genomic profiling and targeted therapy guided by mutational analysis offers the possibility of precision management of refractory advanced adenocarcinoma in the background of neoplastic syndromes.

KW - Afatinib

KW - EGFR

KW - ERBB2

KW - Genomic profiling

KW - Li-Fraumeni syndrome

KW - Lung cancer

KW - Next generation sequencing

UR - http://www.scopus.com/inward/record.url?scp=84905435526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905435526&partnerID=8YFLogxK

U2 - 10.4161/cbt.29173

DO - 10.4161/cbt.29173

M3 - Article

C2 - 24835218

AN - SCOPUS:84905435526

VL - 15

SP - 970

EP - 974

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 8

ER -